Myriad Genetics (MYGN) Accounts Payables (2010 - 2026)

Myriad Genetics (MYGN) has reported Accounts Payables for 17 consecutive years, with $32.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables rose 16.01% year-over-year to $32.6 million; the TTM figure through Mar 2026 stood at $32.6 million (up 16.01% YoY), while the FY2025 annual figure was $30.0 million, down 7.12% from the prior year.
• Accounts Payables advanced to $32.6 million in Q1 2026 per MYGN's latest filing, from $30.0 million in the prior quarter.
• Across five years, Accounts Payables topped out at $39.8 million in Q2 2023 and bottomed at $21.7 million in Q2 2022.
• Historically, Accounts Payables has averaged $30.9 million across 5 years, with a median of $30.9 million in 2025.
• On a YoY basis, Accounts Payables climbed as much as 88.54% in 2022 and fell as far as 23.86% in 2022.
• Myriad Genetics' Accounts Payables stood at $28.8 million in 2022, then decreased by 10.42% to $25.8 million in 2023, then gained by 25.19% to $32.3 million in 2024, then dropped by 7.12% to $30.0 million in 2025, then gained by 8.67% to $32.6 million in 2026.
• Business Quant data shows MYGN's Accounts Payables at $32.6 million in Q1 2026, $30.0 million in Q4 2025, and $31.8 million in Q3 2025.